Biogen, Eisai to push for fast FDA approval for second Alzheimer’s drug

Biogen Inc. (Nasdaq: BIIB) and its Japanese partner, Eisai, plan to push for a fast approval for their second Alzheimer’s disease drug, lecanemab, following the June U.S. Food and Drug Administration approval of Aduhelm.